TNSN07235A1 - Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride - Google Patents

Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride

Info

Publication number: TNSN07235A1
Authority: TN; Tunisia
Prior art keywords: tetrahydro; chloro; methyl; crystalline forms; benzazepine hydrochloride
Prior art date: 2004-12-21

Application number

TNP2007000235A

Other languages

English (en)

Inventor

Rajesh Kumar Agarwal

Iii William L Betts

James A Henshilwood

Yuan-Hon Kiang

Noah Post

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-21

Filing date

2007-06-20

Publication date

2008-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN07235(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-20 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2008-11-21 Publication of TNSN07235A1 publication Critical patent/TNSN07235A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Psychology (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Pregnancy & Childbirth (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

TNP2007000235A 2004-12-21 2007-06-20 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride TNSN07235A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63822104P	2004-12-21	2004-12-21
PCT/US2005/046983 WO2006069363A2 (fr)	2004-12-21	2005-12-20	Formes cristallines d'hydrochlorure de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine

Publications (1)

Publication Number	Publication Date
TNSN07235A1 true TNSN07235A1 (en)	2008-11-21

Family

ID=36602366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2007000235A TNSN07235A1 (en)	2004-12-21	2007-06-20	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride

Country Status (28)

Country	Link
US (4)	US8168624B2 (fr)
EP (3)	EP1838677B1 (fr)
JP (3)	JP5270167B2 (fr)
KR (1)	KR101281919B1 (fr)
CN (2)	CN101084193B (fr)
AT (1)	ATE442359T1 (fr)
AU (1)	AU2005318959B2 (fr)
BR (1)	BRPI0519726B8 (fr)
CA (1)	CA2589988C (fr)
CU (1)	CU20070138A7 (fr)
CY (1)	CY1109599T1 (fr)
DE (1)	DE602005016603D1 (fr)
DK (1)	DK1838677T3 (fr)
EA (2)	EA201200954A1 (fr)
ES (1)	ES2332009T3 (fr)
HR (1)	HRP20090640T1 (fr)
IL (1)	IL183844A (fr)
MA (1)	MA29147B1 (fr)
ME (1)	ME01090B (fr)
NI (1)	NI200700160A (fr)
NZ (2)	NZ589756A (fr)
PL (1)	PL1838677T3 (fr)
PT (1)	PT1838677E (fr)
RS (1)	RS50996B (fr)
SI (1)	SI1838677T1 (fr)
TN (1)	TNSN07235A1 (fr)
WO (1)	WO2006069363A2 (fr)
ZA (1)	ZA200705125B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
MXPA05013364A (es)	2003-06-17	2006-03-17	Arena Pharm Inc	Procedimiento para preparar 3-benzazepinas.
CA2529320C (fr)	2003-06-17	2013-03-05	Arena Pharmaceuticals, Inc.	Derives de benzazepine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5ht2c
ATE442359T1 (de)	2004-12-21	2009-09-15	Arena Pharm Inc	Kristalline formen von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-be zazepinhydrochlorid
SG158168A1 (en)	2004-12-23	2010-01-29	Arena Pharm Inc	5ht2c receptor modulator compositions and methods of use
US7994163B2 (en)	2005-09-01	2011-08-09	Eli Lilly And Company	6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
PL1924561T3 (pl)	2005-09-01	2013-03-29	Lilly Co Eli	6-aryloalkiloamino-2,3,4,5-tetrahydro-1h-benzo[d]azepiny jako agoniści receptora 5-ht2c
CA2619450C (fr)	2005-09-01	2013-10-22	Eli Lilly And Company	2,3,4,5-tetrahydro-1h-benzo[d]azepines substituees par un heterocycle a liaison 6-n en tant qu'agonistes de recepteur 5-ht2c
SI1926712T1 (sl)	2005-09-01	2010-01-29	Lilly Co Eli	6-substituirani 2,3.4,5-tetrahidro-1h-benzo(d)azepini kot agonisti 5-ht2c receptorja
WO2007120517A2 (fr)	2006-04-03	2007-10-25	Arena Pharmaceuticals, Inc.	Procédés de préparation de 8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazépine et produits intermédiaires associés
US7897595B2 (en)	2006-05-26	2011-03-01	Forest Laboratories Holdings Limited	Pyridoazepine derivatives
CA2670285A1 (fr)	2006-12-05	2008-06-12	Arena Pharmaceuticals, Inc.	Procedes de preparation de (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine et intermediaires de celle-ci
CN102015591B (zh)	2008-03-04	2014-01-29	艾尼纳制药公司	制备与5-ht2c激动剂(r)-8-氯-1-甲基-2，3，4，5-四氢-1h-3-苯并氮杂卓相关的中间体的方法
US8952197B2 (en)	2009-06-18	2015-02-10	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
US9045431B2 (en)	2010-06-02	2015-06-02	Arena Pharmaceuticals, Inc.	Processes for the preparation of 5-HT2C receptor agonists
CA3050049A1 (fr) *	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Formes galeniques a liberation modifiee d'agonistes de 5-ht2c, utiles pour la gestion du poids
CA2808904A1 (fr)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Sels non hygroscopiques d'agonistes de 5-ht2c
SG188363A1 (en)	2010-09-01	2013-04-30	Arena Pharm Inc	Fast-dissolve dosage forms of 5-ht2c agonists
SG10201506896RA (en)	2010-09-01	2015-10-29	Arena Pharm Inc	Administration of lorcaserin to individuals with renal impairment
US20130267500A1 (en)	2010-09-01	2013-10-10	Arena Pharmaceuticals, Inc.	5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
AU2015268758B2 (en) *	2010-09-01	2017-08-24	Arena Pharmaceuticals, Inc.	Modified-release dosage forms of 5-HT2c agonists useful for weight management
CA2808909A1 (fr)	2010-09-01	2012-03-08	Arena Pharmaceuticals, Inc.	Sels de lorcaserine dotes d'acides optiquement actifs
MX2015004532A (es) *	2012-10-09	2016-01-20	Arena Pharm Inc	Metodo de control del peso.
EP2868656A1 (fr)	2013-11-05	2015-05-06	LEK Pharmaceuticals d.d.	Hydrochlorure de lorcasérine amorphe stabilisé
WO2015102017A1 (fr) *	2013-11-13	2015-07-09	Cadila Healthcare Limited	Procédés de préparation de lorcaserin
CN104936947B (zh) *	2013-12-27	2017-03-08	杭州普晒医药科技有限公司	氯卡色林盐及其晶体、其制备方法和用途
EP2924024A3 (fr)	2014-03-21	2016-01-20	Medichem, S.A.	Formes solides de composés d'hydrochlorure de lorcaserin
CN105228986B (zh) *	2014-04-21	2017-11-07	杭州普晒医药科技有限公司	一种氯卡色林共晶及其制备方法、药物组合物和用途
WO2015170346A1 (fr)	2014-05-09	2015-11-12	Council Of Scientific & Industrial Research	Procédé de préparation de 8-chloro-1-méthyl -2,3,4,5-tétrahydro-1h-benzo[d]azépine et de ses énantiomères
TW201618787A (zh)	2014-10-30	2016-06-01	艾尼納製藥公司	組合物及方法
CN104829532A (zh) *	2015-05-15	2015-08-12	浙江理工大学	一种制备绿卡色林盐酸盐单晶的方法
CN104844512B (zh) *	2015-05-15	2017-03-29	东北制药集团股份有限公司	一种绿卡色林盐酸盐半水合物晶型的制备方法
NO346258B1 (en) *	2015-06-30	2022-05-16	Neurad Ltd	Novel breathing control modulating compounds, and methods of making and using same
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP6770775B2 (ja)	2015-10-16	2020-10-21	アッヴィ・インコーポレイテッド	（３Ｓ，４Ｒ）−３−エチル−４−（３Ｈ−イミダゾ［１，２−ａ］ピロロ［２，３−ｅ］−ピラジン−８−イル）−Ｎ−（２，２，２−トリフルオロエチル）ピロリジン−１−カルボキサミドおよびそれの固体型の製造方法
EP3210975A1 (fr)	2016-02-24	2017-08-30	Enantia, S.L.	Co-cristaux de lorcaserine
CN106478506B (zh) *	2016-09-30	2019-03-15	山东科兴生物制品有限公司	半水绿卡色林盐酸盐的制备方法
CN112704670B (zh) *	2021-01-08	2022-07-15	安徽中医药大学	一种盐酸氯卡色林渗透泵控释制剂及其制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH498122A (de)	1968-02-09	1970-10-31	Geigy Ag J R	Verfahren zur Herstellung eines neuen Tetrahydroazepinderivates
CH481110A (de)	1967-02-17	1969-11-15	Geigy Ag J R	Verfahren zur Herstellung von 1,2,4,5-Tetrahydro-3-azepinen
CH500194A (de)	1968-02-15	1970-12-15	Ciba Geigy Ag	Verfahren zur Herstellung von Tetrahydroazepinderivaten
CA974989A (en)	1968-03-11	1975-09-23	Wallace And Tiernan Inc.	Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby
US4233217A (en)	1968-03-11	1980-11-11	Pennwalt Corporation	Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
FR7736M (fr)	1968-09-02	1970-03-09
US3716639A (en)	1970-03-11	1973-02-13	Ciba Geigy Corp	Anorexigenic tetrahydrobenzazepines
US3795683A (en)	1970-08-19	1974-03-05	Hoffmann La Roche	2,3,4,5-tetrahydro-1h-3-benzazepines
LU65954A1 (fr)	1972-08-25	1974-03-07
US4210749A (en)	1974-11-12	1980-07-01	Pennwalt Corporation	Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US4111957A (en)	1977-02-02	1978-09-05	Smithkline Corporation	Substituted 1-thienyl and furyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds
US4108989A (en)	1977-04-01	1978-08-22	Smithkline Corporation	2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diones
CA1090797A (fr)	1978-06-20	1980-12-02	Kenneth G. Holden	Composes a base de 2,3,4,5-tetrahydro-1h-3- benzazepine a substitution en 1 par un groupement thienyle ou un groupement furyle
AU515236B2 (en)	1978-06-26	1981-03-26	Smithkline Corporation	Substituted-1-thienyl and furyl-2,3,4,5-tetrahydro-14-3 benzazepine derivatives
ZA792785B (en)	1978-07-07	1980-08-27	Smithkline Corp	Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
EP0080779B1 (fr)	1981-11-27	1986-07-16	Smithkline Beckman Corporation	3-Benzazépines comme antagonistes-alpha-2
FR2525603A1 (fr)	1982-04-27	1983-10-28	Adir	Benzoazacycloalkyl-spiro-imidazolinines, leur preparation et leur application en therapeutique
US4988690A (en)	1982-06-14	1991-01-29	Hoechst-Roussel Pharmaceuticals Inc.	1-aryloxy-2,3,4,5-tetrahydro-3-benzazepines and anti-depressant use thereof
US4541954A (en)	1984-09-05	1985-09-17	Smithkline Beckman Corporation	Method for preparing 6-chloro-N-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4762845A (en)	1986-05-21	1988-08-09	Abbott Laboratories	7-(3-Substituted imino-1-pyrrolidinyl)-quinolone-3-carboxylic acids
EP0285287A3 (fr)	1987-03-23	1990-08-16	Smithkline Beecham Corporation	Emploi de 3-benzazépines pour le traitement des troubles de la mobilité gastro-intestinale
US5015639A (en)	1987-03-27	1991-05-14	Schering Corporation	Substituted benzazepines, their preparation and pharmaceutical compositions containing them
ZA882080B (en)	1987-03-27	1989-04-26	Schering Corp	Substituted benzazepines,their preparation and pharmaceutical compositions containing them
WO1988007858A1 (fr)	1987-04-09	1988-10-20	Smithkline Beckman Corporation	Benzazepines substituees en position 3 par un groupe sulfinyle et sulfonyle
US5422355A (en)	1989-06-02	1995-06-06	John Wyeth & Brother, Limited	Composition for treating depression with (N-heteroaryl)alkylamines
US5178786A (en)	1989-08-04	1993-01-12	The Lubrizol Corporation	Corrosion-inhibiting compositions and functional fluids containing same
AU8201591A (en)	1990-06-15	1992-01-07	Schering Corporation	8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them
US5275915A (en)	1991-06-05	1994-01-04	Dainippon Ink And Chemicals, Inc.	Developer for light-sensitive material
EP0589973A1 (fr)	1991-06-21	1994-04-06	Smithkline Beecham Plc	Medicaments
EP0558824A1 (fr)	1992-02-04	1993-09-08	Duphar International Research B.V	Procédé pour la préparation d'aminoalcools vicinaux et de leurs dérivés protégés optiquement actifs
JPH05339263A (ja)	1992-06-08	1993-12-21	Wakunaga Pharmaceut Co Ltd	ジヒドロピリジン誘導体
JPH06298746A (ja)	1993-04-19	1994-10-25	Showa Denko Kk	環状イミド酸エステルの製造法
US6087346A (en)	1993-06-23	2000-07-11	Cambridge Neuroscience, Inc.	Sigma receptor ligands and the use thereof
US5387685A (en)	1993-07-16	1995-02-07	American Cyanamid Co	MDR reversal agents
GB9322976D0 (en)	1993-11-08	1994-01-05	Pfizer Ltd	Therapeutic agents
DE4419247A1 (de)	1994-06-01	1995-12-07	Merckle Gmbh	Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
DE4419246A1 (de)	1994-06-01	1995-12-07	Merckle Gmbh	Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4419315A1 (de)	1994-06-01	1995-12-07	Merckle Gmbh	Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
DE4427838A1 (de)	1994-08-05	1996-02-08	Thomae Gmbh Dr K	Kondensierte Azepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4429079A1 (de)	1994-08-17	1996-02-22	Thomae Gmbh Dr K	Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH08134048A (ja)	1994-11-08	1996-05-28	Sumitomo Chem Co Ltd	オキサゾリン類の製造法
GB9508622D0 (en)	1995-04-28	1995-06-14	Pfizer Ltd	Therapeutic agants
JPH0930960A (ja)	1995-07-18	1997-02-04	Takasago Internatl Corp	真菌感染症治療剤
JPH0987258A (ja)	1995-09-28	1997-03-31	Sumitomo Chem Co Ltd	オキサゾリン類、その製造方法およびそれを用いる不斉シクロプロパンカルボン酸類の製造方法
CA2190708A1 (fr)	1995-12-08	1997-06-09	Johannes Aebi	Derives de substitution aminoalkyles de composes benzo-heterocycliques
US5892116A (en)	1996-01-03	1999-04-06	Georgetown University	Gelators
US5925651A (en)	1996-04-03	1999-07-20	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5691362A (en)	1996-06-05	1997-11-25	Schering-Plough Corporation	Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists
EP0920417A4 (fr)	1996-08-15	1999-12-29	Smithkline Beecham Corp	Antagonistes du recepteur de l'il-8
AU6290998A (en)	1997-03-07	1998-09-29	Novo Nordisk A/S	4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
AUPP020297A0 (en)	1997-11-05	1997-11-27	University Of Melbourne, The	A novel receptor, and compounds which bind thereto
EP0987235B1 (fr)	1998-08-25	2003-03-12	MERCK PATENT GmbH	Procédé pour la conversion d'arènes ou d'alkènes avec des iodoalkènes, des aryliodides ou des sels arènediazonium
DE60006618T2 (de)	1999-08-06	2004-09-23	F. Hoffmann-La Roche Ag	Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
EP1074549B1 (fr)	1999-08-06	2003-11-19	F. Hoffmann-La Roche Ag	Tétrahydro-benzo(d)azépines et leurs utilisations en tant qu'antagonistes du récepteur de glutamate métabotropique
DE10003708A1 (de)	2000-01-28	2001-08-02	Solvent Innovation Gmbh	Neuartige chirale ionische Flüssigkeiten und Verfahren zu ihrer Darstellung in enantiomerenreiner oder enantiomerenangereicherter Form
AR035369A1 (es)	2000-11-14	2004-05-12	Smithkline Beecham Plc	Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
GB0030710D0 (en)	2000-12-15	2001-01-31	Hoffmann La Roche	Piperazine derivatives
WO2002074746A1 (fr)	2001-03-16	2002-09-26	Yamanouchi Pharmaceutical Co., Ltd.	Derives de benzazepine
DE10119278C1 (de)	2001-04-20	2002-10-02	Merck Patent Gmbh	Verfahren zur Herstellung von Fluoralkylphosphaten
US6825198B2 (en)	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
MXPA04002785A (es)	2001-09-24	2004-07-29	Elan Pharm Inc	Aminas sustituidas para tratamiento de enfermedad de alzheimer.
AU2003214873A1 (en)	2002-01-18	2003-09-02	Ceretek Llc	Methods of treating conditions associated with an edg receptor
ATE486842T1 (de)	2002-03-12	2010-11-15	Merck Sharp & Dohme	Substituierte amide
US6953787B2 (en)	2002-04-12	2005-10-11	Arena Pharmaceuticals, Inc.	5HT2C receptor modulators
GB0224557D0 (en)	2002-10-22	2002-11-27	Glaxo Group Ltd	Novel compounds
MXPA05013364A (es)	2003-06-17	2006-03-17	Arena Pharm Inc	Procedimiento para preparar 3-benzazepinas.
CA2529320C (fr)	2003-06-17	2013-03-05	Arena Pharmaceuticals, Inc.	Derives de benzazepine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5ht2c
US20080009478A1 (en)	2003-10-22	2008-01-10	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases
US20070275949A1 (en)	2003-10-22	2007-11-29	Arena Pharmaceuticals, Inc.	Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
WO2006013209A2 (fr)	2004-08-02	2006-02-09	Genmedica Therapeutics Sl	Composes inhibant les amine oxydases contenant du cuivre, et utilisations correspondantes
WO2006043710A1 (fr)	2004-10-19	2006-04-27	Reverse Proteomics Research Institute Co., Ltd.	Protéine cible et gène cible pour le développement de médicaments et procédé de recherche par criblage
ATE442359T1 (de)	2004-12-21	2009-09-15	Arena Pharm Inc	Kristalline formen von (r)-8-chlor-1-methyl-2,3,4,5-tetrahydro-1h-3-be zazepinhydrochlorid
SG158168A1 (en)	2004-12-23	2010-01-29	Arena Pharm Inc	5ht2c receptor modulator compositions and methods of use
WO2007120517A2 (fr)	2006-04-03	2007-10-25	Arena Pharmaceuticals, Inc.	Procédés de préparation de 8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazépine et produits intermédiaires associés
JP5339263B2 (ja)	2007-07-26	2013-11-13	コクヨ株式会社	引き戸の取付構造、引き戸及び収納装置

2005
- 2005-12-20 AT AT05855526T patent/ATE442359T1/de active
- 2005-12-20 CA CA2589988A patent/CA2589988C/fr active Active
- 2005-12-20 NZ NZ589756A patent/NZ589756A/en not_active IP Right Cessation
- 2005-12-20 CN CN2005800433929A patent/CN101084193B/zh active Active
- 2005-12-20 AU AU2005318959A patent/AU2005318959B2/en active Active
- 2005-12-20 RS RSP-2009/0476A patent/RS50996B/sr unknown
- 2005-12-20 WO PCT/US2005/046983 patent/WO2006069363A2/fr not_active Ceased
- 2005-12-20 PL PL05855526T patent/PL1838677T3/pl unknown
- 2005-12-20 PT PT05855526T patent/PT1838677E/pt unknown
- 2005-12-20 DK DK05855526T patent/DK1838677T3/da active
- 2005-12-20 EP EP05855526A patent/EP1838677B1/fr active Active
- 2005-12-20 KR KR1020077016727A patent/KR101281919B1/ko active Active
- 2005-12-20 SI SI200530839T patent/SI1838677T1/sl unknown
- 2005-12-20 NZ NZ555981A patent/NZ555981A/en not_active IP Right Cessation
- 2005-12-20 DE DE602005016603T patent/DE602005016603D1/de active Active
- 2005-12-20 ME MEP-2009-338A patent/ME01090B/fr unknown
- 2005-12-20 EP EP09011453A patent/EP2149562A1/fr not_active Withdrawn
- 2005-12-20 EP EP10010048.6A patent/EP2327698B1/fr active Active
- 2005-12-20 CN CN2011103046342A patent/CN102321023A/zh active Pending
- 2005-12-20 EA EA201200954A patent/EA201200954A1/ru unknown
- 2005-12-20 BR BRPI0519726A patent/BRPI0519726B8/pt active IP Right Grant
- 2005-12-20 HR HR20090640T patent/HRP20090640T1/hr unknown
- 2005-12-20 US US11/793,473 patent/US8168624B2/en active Active
- 2005-12-20 JP JP2007547060A patent/JP5270167B2/ja active Active
- 2005-12-20 EA EA200701358A patent/EA017894B1/ru unknown
- 2005-12-20 ES ES05855526T patent/ES2332009T3/es active Active
2007
- 2007-06-11 IL IL183844A patent/IL183844A/en active IP Right Grant
- 2007-06-15 CU CU20070138A patent/CU20070138A7/es unknown
- 2007-06-20 ZA ZA2007/05125A patent/ZA200705125B/en unknown
- 2007-06-20 TN TNP2007000235A patent/TNSN07235A1/fr unknown
- 2007-06-21 NI NI200700160A patent/NI200700160A/es unknown
- 2007-07-12 MA MA30070A patent/MA29147B1/fr unknown
2009
- 2009-11-10 CY CY20091101162T patent/CY1109599T1/el unknown
2012
- 2012-03-21 US US13/425,669 patent/US8697686B2/en active Active
- 2012-05-18 JP JP2012114460A patent/JP5781008B2/ja active Active
- 2012-09-14 US US13/616,887 patent/US8980881B2/en active Active
2014
- 2014-06-02 JP JP2014113743A patent/JP2014156490A/ja active Pending
2015
- 2015-03-02 US US14/635,146 patent/US20160009654A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2005318959A1 (en)	2006-06-29
DE602005016603D1 (de)	2009-10-22
CN101084193B (zh)	2011-12-07
EA201200954A1 (ru)	2013-05-30
CA2589988C (fr)	2017-02-14
MA29147B1 (fr)	2008-01-02
HK1102812A1 (en)	2007-12-07
IL183844A (en)	2013-11-28
CY1109599T1 (el)	2014-08-13
EP2327698A1 (fr)	2011-06-01
EP2149562A1 (fr)	2010-02-03
CN101084193A (zh)	2007-12-05
PT1838677E (pt)	2009-11-16
CN102321023A (zh)	2012-01-18
EP1838677A2 (fr)	2007-10-03
NZ555981A (en)	2011-01-28
PL1838677T3 (pl)	2010-02-26
AU2005318959B2 (en)	2011-12-15
NZ589756A (en)	2012-05-25
BRPI0519726B1 (pt)	2020-11-24
JP2014156490A (ja)	2014-08-28
US8168624B2 (en)	2012-05-01
IL183844A0 (en)	2007-10-31
WO2006069363A2 (fr)	2006-06-29
US8697686B2 (en)	2014-04-15
JP5781008B2 (ja)	2015-09-16
KR20070098870A (ko)	2007-10-05
HK1157334A1 (en)	2012-06-29
BRPI0519726B8 (pt)	2021-05-25
ES2332009T3 (es)	2010-01-22
ME01090B (fr)	2012-12-20
RS50996B (sr)	2010-10-31
HRP20090640T1 (hr)	2010-01-31
JP2008524262A (ja)	2008-07-10
KR101281919B1 (ko)	2013-07-03
US20120264743A1 (en)	2012-10-18
EP2327698B1 (fr)	2015-08-05
US20100004223A1 (en)	2010-01-07
JP5270167B2 (ja)	2013-08-21
SI1838677T1 (sl)	2010-01-29
CU20070138A7 (es)	2010-01-22
US20140051684A1 (en)	2014-02-20
ATE442359T1 (de)	2009-09-15
EA200701358A1 (ru)	2007-12-28
NI200700160A (es)	2008-04-21
BRPI0519726A2 (pt)	2009-03-10
DK1838677T3 (da)	2010-01-11
WO2006069363A3 (fr)	2007-05-10
US20160009654A1 (en)	2016-01-14
JP2012153727A (ja)	2012-08-16
US8980881B2 (en)	2015-03-17
ZA200705125B (en)	2011-07-27
EA017894B1 (ru)	2013-04-30
EP1838677B1 (fr)	2009-09-09
CA2589988A1 (fr)	2006-06-29

Publication	Publication Date	Title
TNSN07235A1 (en)	2008-11-21	Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
MXPA04008772A (es)	2004-12-06	Composiciones de clorhidrato de naltrexona.
AU3652102A (en)	2002-06-11	Compounds and their uses
MX2007005221A (es)	2007-06-22	Formas cristalinas de ascomicina y preparacion de ellas.
MXPA05009969A (es)	2006-02-17	Metodo para aislar la forma cristalina i de la 5-azacitidina.
TW200510325A (en)	2005-03-16	2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
GB0305704D0 (en)	2003-04-16	Radiofluorination methods
WO2004069152A3 (fr)	2006-04-27	?4,5 glycuronidase et ses utilisations
AU2003228770A8 (en)	2003-11-11	Substituted pyrazolopyrimidines
TW200621737A (en)	2006-07-01	2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TW200606149A (en)	2006-02-16	Crystalline polymorph of bazedoxifene acetate
TW200716583A (en)	2007-05-01	Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
IL160171A0 (en)	2004-07-25	Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
MY133969A (en)	2007-11-30	Indoloquinazolinones
UA86055C2 (ru)	2009-03-25	Кристаллическая форма в базедоксифена ацетата
TW200613308A (en)	2006-05-01	Cyclobutanetetracarboxylate compound and preparation method thereof
MXPA05008960A (es)	2005-11-04	Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
TW200605863A (en)	2006-02-16	Bazedoxifene acetate formulations
DE60201074D1 (en)	2004-09-30	Pyrazolopyridinderivate
MXPA06003345A (es)	2006-06-08	Derivados de aminopiridina como inhibidores de la no-sintasa inducible.
AU1142502A (en)	2002-04-15	Novel crystalline forms of a factor xa inhibitor
UA85703C2 (en)	2009-02-25	Crystalline polymorph of bazedoxifene acetate
MXPA05006587A (es)	2005-12-14	Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
DE60212130D1 (en)	2006-07-20	Carvedilolpolymorph
WO2006097809A3 (fr)	2007-04-26	Nouveaux derives de tyrosine